Apontis Pharma Future Growth
Future criteria checks 4/6
Apontis Pharma is forecast to grow earnings and revenue by 76% and 17.5% per annum respectively. EPS is expected to grow by 76.2% per annum. Return on equity is forecast to be 18.8% in 3 years.
Key information
76.0%
Earnings growth rate
76.2%
EPS growth rate
Pharmaceuticals earnings growth | 21.7% |
Revenue growth rate | 17.5% |
Future return on equity | 18.8% |
Analyst coverage | Low |
Last updated | 24 Jun 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 71 | 7 | 6 | 11 | 4 |
12/31/2025 | 59 | 4 | 1 | 7 | 4 |
12/31/2024 | 51 | 1 | -11 | -6 | 4 |
12/31/2023 | 37 | -11 | -16 | -13 | N/A |
9/30/2023 | 42 | -7 | -11 | -8 | N/A |
6/30/2023 | 46 | -3 | -6 | -3 | N/A |
3/31/2023 | 51 | 0 | 1 | 4 | N/A |
12/31/2022 | 56 | 3 | 8 | 11 | N/A |
9/30/2022 | 56 | 3 | 5 | 8 | N/A |
6/30/2022 | 56 | 4 | 3 | 6 | N/A |
3/31/2022 | 54 | 2 | 2 | 5 | N/A |
12/31/2021 | 51 | -1 | 2 | 3 | N/A |
9/30/2021 | 48 | -1 | 4 | 5 | N/A |
6/30/2021 | 46 | -1 | 6 | 6 | N/A |
3/31/2021 | 42 | -1 | 3 | 4 | N/A |
12/31/2020 | 39 | -1 | 1 | 1 | N/A |
12/31/2019 | 40 | -2 | -1 | 0 | N/A |
12/31/2018 | 20 | 0 | 0 | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).
Earnings vs Market: APPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: APPH is expected to become profitable in the next 3 years.
Revenue vs Market: APPH's revenue (17.5% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: APPH's revenue (17.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APPH's Return on Equity is forecast to be low in 3 years time (18.8%).